Compile Data Set for Download or QSAR
maximum 50k data
Found 62 of ph data with Target = 'cGMP-dependent 3',5'-cyclic phosphodiesterase'
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50166893(2-(3,4-Dimethoxy-benzyl)-7-[(R)-1-((R)-1-hydroxy-e...)
Affinity DataIC50:  1nMpH: 7.2 T: 2°CAssay Description:Assay: PDE2A is assayed with FL-cAMP as substrate. An enzyme titration is first performed to determine the working concentration of PDE. The concentr...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50444038(CHEMBL3092563 | US9669035, B-5)
Affinity DataIC50:  1.40nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50425123(CHEMBL2313234 | US9669035, B-3)
Affinity DataIC50:  2.30nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50026827(CHEMBL3331516 | US9669035, B-6)
Affinity DataIC50:  4.80nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM292716(1-(2-Chloro-5-(cyclobutylmethoxy)phenyl)-8-methoxy...)
Affinity DataIC50:  5.90nMpH: 7.2 T: 2°CAssay Description:Assay: PDE2A is assayed with FL-cAMP as substrate. An enzyme titration is first performed to determine the working concentration of PDE. The concentr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50026829(CHEMBL3331514 | US9669035, B-7)
Affinity DataIC50:  6.20nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50026828(CHEMBL3331515 | US9669035, B-8)
Affinity DataIC50:  6.5nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50026821(CHEMBL3331521 | US11419874, Example 10 | US9669035...)
Affinity DataIC50:  7.40nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50026826(CHEMBL3331517 | US11419874, Example 9 | US9669035,...)
Affinity DataIC50:  7.80nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM292715(1-(5-Butoxy-2-chlorophenyl)-8-methoxy-3-methyl-1H-...)
Affinity DataIC50:  9.40nMpH: 7.2 T: 2°CAssay Description:Assay: PDE2A is assayed with FL-cAMP as substrate. An enzyme titration is first performed to determine the working concentration of PDE. The concentr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM179970(US9669035, B-9)
Affinity DataIC50:  9.5nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50026820(CHEMBL3331513 | US9669035, B-10)
Affinity DataIC50:  10nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM179972(US9669035, B-11)
Affinity DataIC50:  11nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50026825(CHEMBL3331518 | US9669035, B-12)
Affinity DataIC50:  12nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM292713(1-(5-Butoxy-2-chlorophenyl)-8-chloro-3-methyl-1H-p...)
Affinity DataIC50:  12nMpH: 7.2 T: 2°CAssay Description:Assay: PDE2A is assayed with FL-cAMP as substrate. An enzyme titration is first performed to determine the working concentration of PDE. The concentr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50026821(CHEMBL3331521 | US11419874, Example 10 | US9669035...)
Affinity DataIC50:  13nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM181755(US9669035, B-25)
Affinity DataIC50:  18nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50425124(CHEMBL2313233 | US9669035, B-13)
Affinity DataIC50:  20nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50425125(CHEMBL2313232 | US9669035, B-4)
Affinity DataIC50:  20nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM179977(US9669035, B-14)
Affinity DataIC50:  21nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM179978(US9669035, B-15)
Affinity DataIC50:  22nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM181763(US9669035, B-26)
Affinity DataIC50:  22nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM292714(1-(5-Butoxy-2-chlorophenyl)-3-methyl-1H-pyrazolo[4...)
Affinity DataIC50:  28nMpH: 7.2 T: 2°CAssay Description:Assay: PDE2A is assayed with FL-cAMP as substrate. An enzyme titration is first performed to determine the working concentration of PDE. The concentr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM50026824(CHEMBL3331519 | US9669035, B-16)
Affinity DataIC50:  30nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM179980(US9669035, B-17)
Affinity DataIC50:  35nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM179981(US9669035, B-18)
Affinity DataIC50:  36nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM181676(US9669035, B-22a)
Affinity DataIC50:  44nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM179983(US9669035, B-20)
Affinity DataIC50:  45nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM179982(US9669035, B-19)
Affinity DataIC50:  46nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM181673(US9669035, B-21)
Affinity DataIC50:  49nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM181678(US9669035, B-23)
Affinity DataIC50:  52nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM162879(US11419874, Example 28 | US9056863, Example Ic1)
Affinity DataIC50:  69nMpH: 7.6 T: 2°CAssay Description:A typical PDE2A assay was performed as follows: the assay was performed in 60 μL samples containing a fixed amount of the PDE2A enzyme (sufficie...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM292712(8-Chloro-1-(2,5-dichlorophenyl)-3-methyl-1H-pyrazo...)
Affinity DataIC50:  73nMpH: 7.2 T: 2°CAssay Description:Assay: PDE2A is assayed with FL-cAMP as substrate. An enzyme titration is first performed to determine the working concentration of PDE. The concentr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM182096(US9669035, B-27)
Affinity DataIC50:  74nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM182226(US9669035, B-28)
Affinity DataIC50:  91nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM182234(US9669035, B-29)
Affinity DataIC50:  120nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM182294(US9669035, B-30)
Affinity DataIC50:  130nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM181713(US9669035, B-24)
Affinity DataIC50:  190nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM182857(US9669035, B-31)
Affinity DataIC50:  330nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM182858(US9669035, B-32)
Affinity DataIC50:  350nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM162878(US9056863, Example Ib1)
Affinity DataIC50:  471nMpH: 7.6 T: 2°CAssay Description:A typical PDE2A assay was performed as follows: the assay was performed in 60 μL samples containing a fixed amount of the PDE2A enzyme (sufficie...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM162877(US9056863, Example Ia2)
Affinity DataIC50:  504nMpH: 7.6 T: 2°CAssay Description:A typical PDE2A assay was performed as follows: the assay was performed in 60 μL samples containing a fixed amount of the PDE2A enzyme (sufficie...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM22926(3-(6-amino-9H-purin-9-yl)nonan-2-ol | EHNA | Eryth...)
Affinity DataIC50:  800nMpH: 7.5 T: 2°CAssay Description:Enzymatic activities were assayed using [3H] cAMP and [3H]cGMP as substrate.More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM119850(US8691986, 17 | US9718803, 5.19)
Affinity DataIC50:  2.16E+3nMpH: 7.2 T: 2°CAssay Description:IMAP TR-FRET progressive binding system, FAM-cAMP substrate were from Molecular Devices (Sunnyvale, Calif.). The PDE IMAP assay was conducted in a 3...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM119849(US8691986, 16 | US9718803, 30.4)
Affinity DataIC50:  3.30E+3nMpH: 7.2 T: 2°CAssay Description:IMAP TR-FRET progressive binding system, FAM-cAMP substrate were from Molecular Devices (Sunnyvale, Calif.). The PDE IMAP assay was conducted in a 3...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM123687(US8741907, 3 | US9067945, 2)
Affinity DataIC50: >4.00E+3nMpH: 7.5Assay Description:The test substances are dissolved in 100% DMSO and serially diluted to determine their in vitro effect on PDE 9A. Typically, serial dilutions from 20...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM123687(US8741907, 3 | US9067945, 2)
Affinity DataIC50: >4.00E+3nMpH: 7.5Assay Description:The test substances are dissolved in 100% DMSO and serially diluted to determine their in vitro effect on PDE 9A. 2 uL portions of the diluted substa...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM119844(US8691986, 10)
Affinity DataIC50:  7.38E+3nMpH: 7.2 T: 2°CAssay Description:IMAP TR-FRET progressive binding system, FAM-cAMP substrate were from Molecular Devices (Sunnyvale, Calif.). The PDE IMAP assay was conducted in a 3...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM119843(US8691986, 9)
Affinity DataIC50:  1.00E+4nMpH: 7.2 T: 2°CAssay Description:IMAP TR-FRET progressive binding system, FAM-cAMP substrate were from Molecular Devices (Sunnyvale, Calif.). The PDE IMAP assay was conducted in a 3...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Intra-Cellular Therapies

US Patent
LigandPNGBDBM119842(US8691986, 8)
Affinity DataIC50:  1.00E+4nMpH: 7.2 T: 2°CAssay Description:IMAP TR-FRET progressive binding system, FAM-cAMP substrate were from Molecular Devices (Sunnyvale, Calif.). The PDE IMAP assay was conducted in a 3...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 62 total ) | Next | Last >>
Jump to: